For medicinal products included in the list referred to in Article 23 of Regulation (EC) No 726/2004 F1in the case of products for sale or supply in Northern Ireland, or the list referred to in regulation 202A, in the case of products for sale or supply in Great Britain, the F2symbol and statement: “F3▼ This medicinal product is subject to additional F4... monitoring”.